1
|
Zhao B, Li H, Tian K, Su Y, Zou Z. Synthesis and antitumor activity of bagasse xylan derivatives modified by graft-esterification and cross-linking. Int J Biol Macromol 2023; 253:126867. [PMID: 37730005 DOI: 10.1016/j.ijbiomac.2023.126867] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2022] [Revised: 09/08/2023] [Accepted: 09/10/2023] [Indexed: 09/22/2023]
Abstract
A crucial aspect in achieving sustainable development of biomass materials is the modification of renewable polysaccharides to create various high-value functional materials. In this paper, bagasse xylan (BX) was used as a raw material to introduce benzyl methacrylate (BMA) through graft copolymerization reaction to generate the intermediate product BX-g-BMA. Subsequently, the target product (CA-BX-g-BMA) was synthesized by catalytic esterification of BX-g-BMA with citric acid (CA) in AmimCl ionic liquid. Meanwhile, the characterization and bioactivity studies of CA-BX-g-BMA were carried out. The graft copolymerization and esterification reactions induced significant changes in the morphological structure of BX and obviously improved its thermal stability and crystallinity. The application of density functional theory (DFT), molecular electrostatic potential (MEP) and molecular docking has revealed that CA-BX-g-BMA possesses multiple active sites, strong biological activity and a strong binding affinity to 6RCF tumor protein with a binding energy of -32.26 kJ/mol. The in vitro antitumor activity of this novel derivative was tested by MTT assay, and the results showed that CA-BX-g-BMA was non-toxic to normal cells and inhibited MDA-MB-231 (breast cancer cells) by up to 32.16 % ± 4.89 %, which is approximately 11 times higher than that of BX. The exploration of these properties is essential to promote future multidisciplinary applications of BX derivatives.
Collapse
Affiliation(s)
- Bin Zhao
- College of Chemistry and Bioengineering, Guilin University of Technology, Guilin 541004, China
| | - Heping Li
- College of Chemistry and Bioengineering, Guilin University of Technology, Guilin 541004, China.
| | - Kexin Tian
- College of Chemistry and Bioengineering, Guilin University of Technology, Guilin 541004, China
| | - Yue Su
- College of Chemistry and Bioengineering, Guilin University of Technology, Guilin 541004, China
| | - Zhiming Zou
- College of Chemistry and Bioengineering, Guilin University of Technology, Guilin 541004, China
| |
Collapse
|
2
|
Falsafi SR, Wang Y, Ashaolu TJ, Sharma M, Rawal S, Patel K, Askari G, Javanmard SH, Rostamabadi H. Biopolymer Nanovehicles for Oral Delivery of Natural Anticancer Agents. ADVANCED FUNCTIONAL MATERIALS 2023; 33. [DOI: 10.1002/adfm.202209419] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/15/2022] [Indexed: 01/06/2025]
Abstract
AbstractCancer is the second leading cause of death throughout the world. Nature‐inspired anticancer agents (NAAs) that are a gift of nature to humanity have been extensively utilized in the alleviation/prevention of the disease due to their numerous pharmacological activities. While the oral route is an ideal and common way of drug administration, the application of NAAs through the oral pathway has been extremely limited owing to their inherent features, e.g., poor solubility, gastrointestinal (GI) instability, and low bioavailability. With the development of nano‐driven encapsulation strategies, polymeric vehicles, especially those with natural origins, have demonstrated a potent platform, which can professionally shield versatile NAAs against GI barricades and safely deliver them to the site of action. In this review, the predicament of orally delivering NAAs and the encapsulation strategy solutions based on biopolymer matrices are summarized. Proof‐of‐concept in vitro/in vivo results are also discussed for oral delivery of these agents by various biopolymer vehicles, which can be found so far from the literature. Last but not the least, the challenges and new opportunities in the field are highlighted.
Collapse
Affiliation(s)
- Seid Reza Falsafi
- Isfahan Endocrine and Metabolism Research Center Isfahan University of Medical Sciences Isfahan 81746‐73461 Iran
| | - Yong Wang
- School of Chemical Engineering UNSW Sydney Sydney NSW 2052 Australia
| | - Tolulope Joshua Ashaolu
- Institute of Research and Development Duy Tan University Da Nang 550000 Viet Nam
- Faculty of Environmental and Chemical Engineering Duy Tan University Da Nang 550000 Viet Nam
| | - Minaxi Sharma
- Laboratoire de Chimie verte et Produits Biobasés Haute Ecole Provinciale de Hainaut‐Condorcet Département AgroBioscience et Chimie 11, Rue de la Sucrerie 7800 ATH Belgium
- Department of Applied Biology University of Science and Technology Ri‐Bhoi Meghalaya 793101 India
| | - Shruti Rawal
- Department of Pharmaceutical Technology L.J. Institute of Pharmacy L J University Ahmedabad 382210 India
- Department of Pharmaceutics Institute of Pharmacy Nirma University S.G. Highway, Chharodi Ahmedabad Gujarat 382481 India
| | - Kaushika Patel
- Department of Pharmaceutical Technology L.J. Institute of Pharmacy L J University Ahmedabad 382210 India
| | - Gholamreza Askari
- Department of Community Nutrition School of Nutrition and Food Science Nutrition and Food Security Research Center Isfahan University of Medical Sciences Isfahan 81746‐73461 Iran
| | - Shaghayegh Haghjooy Javanmard
- Applied Physiology Research Center Cardiovascular Research Institute Isfahan University of Medical Isfahan 81746‐73461 Iran
| | - Hadis Rostamabadi
- Nutrition and Food Security Research Center Isfahan University of Medical Sciences Isfahan 81746‐73461 Iran
| |
Collapse
|
3
|
Chen Y, Wang Z, Wang X, Su M, Xu F, Yang L, Jia L, Zhang Z. Advances in Antitumor Nano-Drug Delivery Systems of 10-Hydroxycamptothecin. Int J Nanomedicine 2022; 17:4227-4259. [PMID: 36134205 PMCID: PMC9482956 DOI: 10.2147/ijn.s377149] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2022] [Accepted: 08/25/2022] [Indexed: 01/10/2023] Open
Abstract
10-Hydroxycamptothecin (HCPT) is a natural plant alkaloid from Camptotheca that shows potent antitumor activity by targeting intracellular topoisomerase I. However, factors such as instability of the lactone ring and insolubility in water have limited the clinical application of this drug. In recent years, unprecedented advances in biomedical nanotechnology have facilitated the development of nano drug delivery systems. It has been found that nanomedicine can significantly improve the stability and water solubility of HCPT. NanoMedicines with different diagnostic and therapeutic functions have been developed to significantly improve the anticancer effect of HCPT. In this paper, we collected reports on HCPT nanomedicines against tumors in the past decade. Based on current research advances, we dissected the current status and limitations of HCPT nanomedicines development and looked forward to future research directions.
Collapse
Affiliation(s)
- Yukun Chen
- Cancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, People's Republic of China
| | - Zhenzhi Wang
- Shaanxi University of Chinese Medicine, Xianyang, 712046, People's Republic of China
| | - Xiaofan Wang
- Department of Oncology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, People's Republic of China
| | - Mingliang Su
- Cancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, People's Republic of China
| | - Fan Xu
- Cancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, People's Republic of China
| | - Lian Yang
- Cancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, People's Republic of China
| | - Lijun Jia
- Cancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, People's Republic of China
| | - Zhanxia Zhang
- Cancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, People's Republic of China
| |
Collapse
|